By exploiting the genetic variation in cancer cells, an already approved cancer drug demonstrated enhanced effects against cancer cells in specific patient groups.

Lisa Bancroft is among thousands of people who have been tested for the faulty BRCA gene since its discovery 30 years ago.

The IDEAL team will test this new model on targets known to be relevant in ovarian cancer, the deadliest of gynecologic ...

The company has discontinued the Phase I/II trial of its only clinical candidate due to a potential “unfavourable ...

In 2021, Kelli Sosa was diagnosed with ovarian cancer. While undergoing chemotherapy and surgeries, doctors determined that ...

Nuvectis Pharma shares fell steeply after updated data from its early-stage study evaluating NXP800 to treat an aggressive type of ovarian cancer showed that a change in the dosing schedule only ...

A University of Iowa researcher is using federal funding to develop a new approach to combat ovarian cancer. According to the ...

When Ellie Wilcock was hit by sharp pains in her abdomen and sudden bouts of fatigue in 2022, she blamed it on a urinary ...

The 5-year OS rates were 46% in the HIPEC group versus 38% in the no-HIPEC group, they noted in Lancet Oncology. The trial ...

Researchers from the Walter and Eliza Hall Institute (WEHI)in Australia have found a new way to predict a subset of patients ...

Researchers found significant differences in ovarian cancer survival among Asian American subgroups, emphasizing the ...

Pegylated liposomal doxorubicin (PLD) has demonstrated safety and efficacy in patients with partially platinum-sensitive, ...